

Ultomiris® (ravulizumab-cwvz)
Effective 10/02/2023

Plan	<input checked="" type="checkbox"/> MassHealth UPPL <input type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit (NLX)		
Specialty Limitations			
Contact Information	Specialty Medications		
	All Plans	Phone: 866-814-5506	Fax: 866-249-6155
	Non-Specialty Medications		
	MassHealth	Phone: 877-433-7643	Fax: 866-255-7569
	Commercial	Phone: 800-294-5979	Fax: 888-836-0730
	Exchange	Phone: 855-582-2022	Fax: 855-245-2134
	Medical Specialty Medications (NLX)		
	All Plans	Phone: 844-345-2803	Fax: 844-851-0882
Exceptions			

Overview

Ultomiris® (ravulizumab-cwvz) is indicated for the treatment of aHUS, generalized MG, and PNH. They are monoclonal antibodies that specifically binds to the complement protein C5 with high affinity, thereby inhibiting its cleavage to C5a and C5b and preventing the generation of the terminal complement complex.

Coverage Guidelines

Authorization may be reviewed on a case by case basis for members who are new to the plan currently receiving treatment with requested medication excluding when the product is obtained as samples or via manufacturer's patient assistance programs.

OR

Authorization may be granted for members when **ONE** of the following criteria are met:

1. The member has a diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)
 - a. The member has received a meningococcal vaccine at least two weeks prior to treatment initiation
 - b. Appropriate dosing
2. The member has a diagnosis of atypical hemolytic uremic syndrome (aHUS)
 - a. The member has received a meningococcal vaccine at least two weeks prior to treatment initiation
 - b. Appropriate dosing
3. The member has a diagnosis of generalized myasthenia gravis (MG)
 - a. Member is ≥ 18 years of age
 - b. Member is AchR antibody positive
 - c. Prescriber is a neurologist or consult notes from a neurology office are provided

- d. Inadequate response, adverse reaction, or contraindication to pyridostigmine
- e. Physician attestation of inadequate response or adverse reaction to **TWO** of the following or contraindication to **ALL** of the following immunosuppressant trials
 - i. azathioprine
 - ii. cyclosporine
 - iii. glucocorticoids (e.g., prednisone)
 - iv. mycophenolate
 - v. tacrolimus
- f. Member has received a meningococcal vaccine at least two weeks prior to treatment initiation
- g. Appropriate dosing

Continuation of Therapy

For aHUS/PNH: Reauthorization by prescriber will infer a positive response to therapy.

For generalized myasthenia gravis: Prescriber must provide documentation of positive response to therapy.

Limitations

1. Initial approvals will be granted for the following:
 - a. PNH/aHUS: 1 year
 - b. MG: 6 months
2. Reauthorizations will be granted for 1 year

References

1. Ultomiris (ravulizumab-cwvz) [prescribing information]. Boston, MA: Alexion Pharmaceuticals; December 2018
2. Lee JW, Sicre de Fontbrune F, Wong Lee L, et al. Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study [published online December 3, 2018]. *Blood*. doi: 10.1182/blood-2018-09-876136
3. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. *Blood* 2019; 133:540
4. Röth A, Rottinghaus ST, Hill A, et al. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. *Blood Adv*. 2018;2(17):2176-2185. doi: 10.1182/bloodadvances.2018020644
5. McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. *MMWR Morb Mortal Wkly Rep* 2017; 66:734

Review History

09/18/2019 – Reviewed

01/22/2020 – Added indication of atypical hemolytic uremic syndrome

02/08/2023 - Reviewed and updated for Feb P&T; matched MH UPPL criteria. Added indication of generalized myasthenia gravis. Updated initial approval durations. Effective 4/1/23.

09/13/23 – Reviewed and updated for P&T. Added step through requirement of pyridostigmine. Added reauthorization criteria. Trial with Vyvgart was removed due to Ultomiris being MBO and is not subject to MH's unification requirements. Effective 10/2/23.

